Human Genome Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.hgsi.com
Clinical Trials
68
Active:37
Completed:24
Trial Phases
4 Phases
Phase 1:26
Phase 2:12
Phase 3:8
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Phase 1
26 (51.0%)Phase 2
12 (23.5%)Phase 3
8 (15.7%)Not Applicable
5 (9.8%)An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Phase 2
Completed
- Conditions
- Therapeutic Treatment of Inhalation Anthrax
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02016963
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT01583530
Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis
Phase 1
Withdrawn
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: HGS1025Drug: Placebo
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Registration Number
- NCT01434576
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01013818
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇬🇧Oxford Cancer and Haematology Centre, Headington, Oxford, United Kingdom
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00732940
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Valerious Medical Group Research Center, Long Beach, California, United States
🇺🇸Tampa Medical Group, PA, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found